ArriVent BioPharma, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
AVBP Nasdaq 2834 arrivent.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for ArriVent BioPharma, Inc.

EGFR Inhibitors Market to Witness Upsurge in Growth at a CAGR of 7.9% During the Forecast Period (2026-2036) Owing to the Entry of Next-generation TKIs, ADCs, and Combination Strategies with Immunotherapy| DelveInsight - Jun 15th, 2026 10:31 am
The Evolving EGFR NSCLC Market: 8 Emerging Late-stage Therapies to Watch | DelveInsight - Jun 1st, 2026 6:31 am
ArriVent BioPharma Reports First Quarter 2026 Financial Results - May 11th, 2026 2:01 pm
A Look At ArriVent BioPharma (AVBP) Valuation After FDA Clears ARR-002 Oncology Candidate - May 10th, 2026 12:08 am
ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers - May 7th, 2026 6:00 am
Are You Looking for a Top Momentum Pick? Why ArriVent BioPharma, Inc. (AVBP) is a Great Choice - Apr 15th, 2026 10:00 am
Are Medical Stocks Lagging AstraZeneca (AZN) This Year? - Apr 13th, 2026 7:40 am
Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 72.44%: Read This Before Placing a Bet - Apr 6th, 2026 7:55 am
Assessing ArriVent BioPharma (AVBP) Valuation After Recent Share Price Momentum And Pipeline Interest - Apr 4th, 2026 7:12 pm
Are Medical Stocks Lagging ArriVent BioPharma, Inc. (AVBP) This Year? - Mar 26th, 2026 7:40 am
ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting - Mar 17th, 2026 3:00 pm
Wall Street Analysts See a 70.37% Upside in ArriVent BioPharma, Inc. (AVBP): Can the Stock Really Move This High? - Mar 10th, 2026 7:55 am
Is ArriVent BioPharma, Inc. (AVBP) Stock Outpacing Its Medical Peers This Year? - Mar 10th, 2026 7:40 am
ArriVent BioPharma Reports Full Year 2025 Financial Results - Mar 5th, 2026 2:01 pm
EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight - Feb 11th, 2026 3:31 pm
Here Are Tuesday’s Top Wall Street Analyst Research Calls: AMETEK, Coty, Janus Henderson, Levi Strauss, Pool Corporation, Southern Copper, and More - Dec 23rd, 2025 6:13 am
ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer - Dec 22nd, 2025 6:00 am
We Think ArriVent BioPharma (NASDAQ:AVBP) Needs To Drive Business Growth Carefully - Nov 12th, 2025 3:34 am
ArriVent BioPharma Reports Third Quarter 2025 Financial Results - Nov 10th, 2025 6:00 am
ArriVent Appoints Brent S. Rice as Chief Commercial Officer - Sep 22nd, 2025 2:05 pm